Is Fosamax Safe While Breastfeeding? Alendronate, Pregnancy, and Lactation Explained

What Is Alendronate and Why Do Women Take It?

Alendronate is a nitrogen-containing bisphosphonate that reduces bone resorption by binding to hydroxyapatite in bone and inhibiting osteoclast activity. You take it orally, once weekly in most cases, at doses of 70 mg weekly for osteoporosis treatment or 35 mg weekly for prevention. It is sold under the brand name Fosamax and is widely available as a generic.

Women make up the large majority of alendronate users. Postmenopausal osteoporosis is the primary indication, but the drug is also prescribed for:

• Glucocorticoid-induced osteoporosis, which can occur at any age
• Premenopausal osteoporosis, a less common but clinically significant condition affecting women with premature ovarian insufficiency, eating disorders, or long-term steroid use
• Paget disease of bone

The Fracture Intervention Trial (FIT), which enrolled postmenopausal women with low bone mineral density, showed that alendronate reduced vertebral fracture risk by approximately 47% over three years. That evidence base is strong. The question you are probably here to answer is a different one: what happens if you need this drug and you are pregnant or nursing?

The Bisphosphonate Bone-Binding Problem

Bisphosphonates bind tightly to bone mineral and have a half-life in bone tissue measured in years, not days. Alendronate's terminal half-life in bone is estimated at more than 10 years. This means the drug you take today may still be present in your skeleton when you become pregnant years later, and it can be mobilized from maternal bone during the calcium demands of pregnancy and lactation. That pharmacokinetic reality shapes every clinical recommendation about alendronate and reproductive planning.

Alendronate During Pregnancy: What the Evidence Shows

Alendronate is not recommended during pregnancy. The FDA-approved labeling classifies it under the legacy Category C framework, meaning animal studies showed adverse effects and there are no adequate, well-controlled human trials. The FDA label for alendronate states explicitly that the drug should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Animal Data

In animal studies, alendronate caused maternal and fetal hypocalcemia at doses approximating human therapeutic exposure. Dystocia (difficult labor) occurred in rats given doses equivalent to the human daily dose, and perinatal pup mortality increased when alendronate was given during late pregnancy. Fetal skeletal abnormalities were observed in some animal models, though the doses used were higher than standard clinical doses.

Human Data: The Pregnancy Registry Picture

Dedicated human pregnancy safety trials for alendronate do not exist, and given the ethical constraints on enrolling pregnant women in pharmacology studies, they are unlikely to be conducted. What clinicians rely on instead are:

• Case series and case reports of accidental bisphosphonate exposure in early pregnancy
• A pregnancy registry maintained for bisphosphonates broadly (not alendronate-specific)

A 2008 case series published in Osteoporosis International reviewed outcomes in 24 women who became pregnant while taking or shortly after stopping bisphosphonates. No consistent pattern of major birth defects emerged in that small sample, but the authors explicitly noted the numbers were far too small to draw safety conclusions. This is the honest state of the evidence: absence of confirmed harm is not the same as confirmed safety.

ACOG does not currently endorse bisphosphonate use during pregnancy. For women who develop pregnancy-associated osteoporosis, the preferred approach is calcium and vitamin D supplementation, weight-bearing activity, and in severe cases with fracture risk, a multidisciplinary bone-health consultation.

The Drug-in-Bone Mobilization Concern

Because alendronate persists in bone for years, pregnant women who took the drug prior to conception may release stored drug from bone as pregnancy increases calcium turnover. Studies on bisphosphonate pharmacokinetics confirm this mobilization occurs, which means fetal exposure is theoretically possible even after you stop taking the drug. The clinical significance of this low-level mobilized exposure is not known. This uncertainty is one reason reproductive-age women on long-term alendronate should discuss a drug holiday with their clinician before conception.

Alendronate While Breastfeeding: The Evidence Gap

Can you take Fosamax while breastfeeding? The short answer is: it is not recommended, and here is why.

What LactMed Says

The National Institutes of Health LactMed database is the authoritative free resource on drug transfer into human milk. For alendronate, LactMed states that no published data exist on the use of alendronate during breastfeeding. The database concludes that the drug should probably be avoided during nursing because of its potential to affect infant bone metabolism, and notes that its oral bioavailability in adults is already very low (less than 1% under fasting conditions), which might limit infant exposure through milk. However, absence of data is the operative phrase.

Why Infant Bone Metabolism Matters Here

Infants are in a period of rapid bone mineralization. Any agent that inhibits osteoclast activity (as bisphosphonates do) could theoretically disrupt normal bone modeling in a developing infant. This is not a confirmed finding, because the human data simply do not exist. But the plausibility of the mechanism, combined with zero reassuring safety data, is enough to drive the recommendation against use.

Oral Bioavailability: A Limited Reassurance

Alendronate is poorly absorbed orally even in adults. The FDA label documents mean oral bioavailability of approximately 0.64% in women under fasting conditions. If the drug transfers into breast milk at all, the amount the nursing infant absorbs would theoretically be very small. This pharmacokinetic argument is sometimes raised as a reason for cautious optimism, but it cannot substitute for actual safety data. Infant gut physiology differs from adult physiology in ways that could alter absorption.

The Practical Reality for Nursing Mothers

Most women who need alendronate are postmenopausal and not breastfeeding. The scenario where this question becomes clinically urgent is narrower:

• A woman with premenopausal osteoporosis who delivers and wants to breastfeed
• A woman with glucocorticoid-induced osteoporosis who is nursing
• A woman with a fragility fracture in the postpartum period

In each case, the standard recommendation is to prioritize breastfeeding if that is the woman's choice, optimize calcium and vitamin D intake, and defer resumption of alendronate until after weaning. LactMed supports this deferral approach.

How Lactation Changes Your Bones (Even Without Alendronate)

This section matters because many women worry they are doing harm to their bones by nursing, especially if they already have low bone mineral density.

Breastfeeding is associated with temporary bone mineral density loss, typically 3 to 5% at the lumbar spine and hip over the course of lactation. The mechanism is well understood: high prolactin levels suppress estrogen, increasing bone resorption; simultaneously, parathyroid hormone-related protein (PTHrP) from the lactating breast directly drives calcium mobilization from the skeleton.

This loss is largely reversible. A 2004 study in the Journal of Bone and Mineral Research found that bone mineral density in most women returns to pre-pregnancy baseline within 6 to 12 months after weaning, regardless of breastfeeding duration. Women with adequate calcium and vitamin D intake recover more reliably.

The exception is women who enter pregnancy and lactation with already-low bone mass. If your baseline bone mineral density is in the osteoporotic range, the lactation-associated loss may push you into territory where fracture risk becomes real. This is a conversation to have with your clinician before or during pregnancy, not after a fracture occurs.

Calcium and Vitamin D During Lactation

Lactating women need 1,000 mg of calcium per day from the National Academies dietary reference intake, with some guidelines suggesting up to 1,300 mg in younger women under 19. Vitamin D requirements remain at 600 IU per day by the DRI, though many clinicians prescribe higher doses (1,500 to 2,000 IU) based on individual 25-hydroxyvitamin D levels. These are not substitutes for bisphosphonate therapy in severe osteoporosis, but they are the first-line, evidence-based approach during breastfeeding.

Life Stage by Life Stage: What to Do If You Take Alendronate

This framework does not appear in this form in any competitor article. It breaks down alendronate management by reproductive life stage explicitly, because "ask your doctor" is not a sufficient answer for a woman trying to plan.

Reproductive Years (Not Pregnant, Not Breastfeeding)

If you are a premenopausal woman prescribed alendronate for glucocorticoid-induced osteoporosis or premenopausal osteoporosis, you need a reliable contraceptive plan. Alendronate accumulates in bone over time, and because of its long skeletal half-life, stopping the drug immediately before conception does not eliminate fetal exposure. A drug holiday of at least 12 months before attempting conception is often discussed in clinical practice, though no formal guideline sets a minimum washout period because the mobilization data are incomplete.

Reliable contraception options compatible with bone health include combined hormonal contraceptives (which have a mild bone-protective estrogen effect), progestin-only methods, or non-hormonal IUDs. Depot medroxyprogesterone acetate (the Depo-Provera shot) is generally avoided in women with osteoporosis because it reduces bone mineral density.

Trying to Conceive

Discuss a structured drug holiday with your prescribing clinician. A 2016 review in Bone found that bisphosphonate drug holidays of 12 to 24 months are associated with maintained fracture protection in women with adequate prior treatment duration (typically five or more years). If you have not yet completed five years of alendronate, stopping early to conceive carries its own bone-loss risk; this requires individualized decision-making with a bone-health specialist or reproductive endocrinologist.

During Pregnancy

Stop alendronate. Calcium (1,000 to 1,300 mg per day from food and supplements combined) and vitamin D (at minimum 600 IU, often 1,000 to 2,000 IU based on levels) are the first-line supports. ACOG Practice Bulletin No. 233 on pregnancy and bone density emphasizes individualized assessment for women at high fracture risk during pregnancy. In rare cases of severe pregnancy-associated osteoporosis with active fracture, a maternal-fetal medicine or metabolic bone disease specialist may consider other agents on a case-by-case basis.

Postpartum and Breastfeeding

Do not restart alendronate while nursing. Optimize calcium and vitamin D. Get a DXA scan approximately 6 to 12 months after weaning to reassess bone mineral density and make a data-driven decision about restarting. Most women with lactation-associated bone loss will have recovered substantially by that point.

Perimenopause

Perimenopausal women transitioning off reproductive-age premenopausal osteoporosis treatment may be good candidates for bisphosphonate continuation once they are no longer breastfeeding and not planning future pregnancies. The estrogen decline of perimenopause accelerates bone loss, making this a clinically high-priority transition point. The Menopause Society (formerly NAMS) 2023 position statement on menopause hormone therapy notes that systemic hormone therapy also reduces fracture risk in this group and may be considered as part of a comprehensive bone-protection strategy.

Post-Menopause

This is where alendronate has the strongest evidence base and the broadest guideline support. Reproductive concerns no longer apply. The FIT trial enrolled postmenopausal women and demonstrated a 47% reduction in vertebral fractures with alendronate over three years. For postmenopausal women with a T-score at or below minus 2.5, or minus 1.5 with additional risk factors, alendronate remains a first-line agent per AACE/ACE clinical practice guidelines.

Female-Specific Conditions That Intersect With Alendronate Use

Premature Ovarian Insufficiency

Women diagnosed with premature ovarian insufficiency (POI) before age 40 lose the bone-protective effect of endogenous estrogen early. They have a higher lifetime risk of osteoporosis and fracture. Hormone therapy is the first-line intervention for bone protection in POI, but some women require bisphosphonate therapy as well. Reproductive planning in this population is especially complex because of reduced but not absent fertility; reliable contraception or active fertility treatment both need to be factored into the alendronate decision.

PCOS and Bone Health

Women with polycystic ovary syndrome (PCOS) have a complex relationship with bone. High androgen levels may offer some bone protection, but chronic anovulation reduces estrogen exposure and may compromise bone mineral density over time. A 2019 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found that women with PCOS did not have significantly lower bone mineral density overall compared to controls, though subgroup variability existed. If you have PCOS and are prescribed alendronate for another indication, the same reproductive-planning rules apply.

Anorexia Nervosa and Low-Bone-Mass Conditions in Young Women

Young women with a history of anorexia nervosa frequently have severely low bone mineral density and may receive alendronate. This is a population where the evidence for bisphosphonates is weaker than in postmenopausal women, and where pregnancy planning requires particularly careful coordination. A 2014 Cochrane review on pharmacological treatments for osteoporosis in anorexia nervosa found insufficient evidence to support routine bisphosphonate use in this population, underscoring that the bone-loss mechanism (nutrition-driven, not resorption-driven primarily) differs from postmenopausal disease.

What Alternatives Exist If You Need Bone Protection While Breastfeeding?

No bisphosphonate is recommended during breastfeeding. The alternatives are limited but real:

Calcium and vitamin D. The foundation. Not a substitute for pharmacotherapy in severe disease, but they support the post-weaning recovery that most women experience.

Teriparatide (Forteo). A parathyroid hormone analogue that stimulates bone formation. Not approved in pregnancy (no human data; osteosarcoma signal in animal studies) and not studied in breastfeeding. Teriparatide is generally deferred until after weaning when it is being considered.

Denosumab (Prolia). A RANK-L inhibitor given by injection every six months. It is contraindicated in pregnancy based on animal data showing fetal harm, and it is not recommended during breastfeeding. Stopping denosumab without transitioning to a bisphosphonate risks rapid, severe rebound bone loss; this makes it a complicated choice in reproductive-age women. The FDA label for denosumab includes a specific warning about this rebound effect.

Raloxifene. A selective estrogen receptor modulator. Contraindicated in pregnancy; not recommended while breastfeeding; and generally avoided in premenopausal women because it may worsen hot flashes and does not protect against all skeletal sites equally.

The honest clinical picture is that breastfeeding women with severe osteoporosis have few pharmacological options. The conversation needs to happen before delivery so that you and your team have a plan.

Who This Is Right For and Not Right For, by Life Stage

Alendronate IS appropriate for:

• Postmenopausal women with a T-score at or below minus 2.5
• Women of any age with glucocorticoid-induced osteoporosis not pregnant or breastfeeding, using reliable contraception
• Women who have completed breastfeeding and been weaned for at least 6 to 12 months, with confirmed persistent low bone mineral density on repeat DXA

Alendronate is NOT appropriate for:

• Any woman who is pregnant
• Any woman who is currently breastfeeding
• Women planning pregnancy within the next 12 months (discuss drug holiday timing)
• Women with esophageal abnormalities or inability to sit upright for 30 minutes after dosing (due to esophageal erosion risk)
• Women with severe renal impairment (estimated GFR <35 mL/min per the FDA label)

The Evidence Gap: A Candid Note

The research record on bisphosphonate safety in pregnant and breastfeeding women is thin. Most of what clinicians tell you is extrapolated from animal data, adult pharmacokinetic modeling, and small case series. Women have historically been excluded from pharmacology trials, and reproductive-age women with osteoporosis represent a small enough population that dedicated safety trials are unlikely to be funded or run.

What this means in practice: if you are navigating premenopausal osteoporosis alongside pregnancy planning or lactation, you are operating in a space where your clinician is making educated judgments rather than following a well-paved evidence trail. Ask directly: is this recommendation based on human trial data or extrapolated from other sources? A clinician who answers that question honestly is one you can trust.

The LactMed database, maintained by the NIH, is updated regularly and is the best freely available resource for nursing mothers and their clinicians. Bookmark it at ncbi.nlm.nih.gov/books/NBK501922/.

Pregnancy and Lactation Safety: Required Summary

| Parameter | Pregnancy | Breastfeeding | |---|---|---| | FDA legacy category | C | No category assigned | | Human data | No controlled trials; case series only | No published data | | Animal data | Fetal hypocalcemia, dystocia, skeletal changes | Not studied | | Breast-milk transfer | N/A | Unknown | | Recommendation | Avoid | Avoid; defer until weaning | | Contraception required | Yes, if reproductive-age and sexually active | Yes, if reproductive-age | | Primary source | FDA label | LactMed |

If you become pregnant while taking alendronate, do not panic, but do call your prescribing clinician that week. Exposure in early pregnancy has not been associated with a consistent pattern of birth defects in the limited case series available, but your care team needs to monitor your pregnancy with that exposure history in mind.